<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="16718" end="16728" sStart="16627" offset="91" sid="r8.suggest.v.0617" wn="3" wnkey="suggest%2:32:02::" text="No nuclear staining was seen in these structures in most non-transgenic animals, suggesting that weak activation of Wnt signaling may occur with overexpression of wild type ?-catenin protein." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="21651" end="21661" sStart="null" offset="229" sid="r8.suggest.v.0524" wn="3" wnkey="suggest%2:32:02::" text="In the transgenic line expressing high levels of human wild-type ?-catenin, significant amounts of FLAG epitope-tagged protein were detected, however overall ?-catenin levels were only slightly increased, suggesting the mechanisms that normally regulate ?-catenin level were able to compensate for the addition of the human transgenic protein." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="5277" end="5285" sStart="null" offset="64" sid="r8.suggest.v.0356" wn="3" wnkey="suggest%2:32:02::" text="The lack of aberrant neuronal proliferation in our mice suggests that differentiated neurons may not be as susceptible to the mitogenic effects of Wnt signaling as are neuroepithelial progenitor cells [ 22 ] ." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-33.anc" start="30947" end="30951" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="19576" end="19582" sStart="null" offset="8" sid="r8.number.n.0836" wn="1" wnkey="number%1:07:00::" text="While a number of transgenic animals died in the first nine months, the percentage of animals surviving was not significantly different between the transgenic and non-transgenic groups (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="18086" end="18092" sStart="null" offset="31" sid="r9.normal.j.0699" wn="3" wnkey="normal%3:00:03::" text="Kinked tails were of normal length or slightly shortened." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-33.anc" start="24873" end="24879" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Thus in our transgenic animals, aberrant Wnt activation appears to be limited to &lt;b&gt;mature&lt;/b&gt;, postmitotic neurons." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-33.anc" start="24873" end="24879" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Thus in our transgenic animals, aberrant Wnt activation appears to be limited to &lt;b&gt;mature&lt;/b&gt;, postmitotic neurons." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-33.anc" start="24873" end="24879" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Thus in our transgenic animals, aberrant Wnt activation appears to be limited to &lt;b&gt;mature&lt;/b&gt;, postmitotic neurons." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-33.anc" start="24873" end="24879" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Thus in our transgenic animals, aberrant Wnt activation appears to be limited to &lt;b&gt;mature&lt;/b&gt;, postmitotic neurons." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-33.anc" start="24873" end="24879" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Thus in our transgenic animals, aberrant Wnt activation appears to be limited to &lt;b&gt;mature&lt;/b&gt;, postmitotic neurons." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-33.anc" start="24873" end="24879" sStart="null" offset="0" sid="null" wn="1" wnkey="mature%2:30:00::" text="Thus in our transgenic animals, aberrant Wnt activation appears to be limited to &lt;b&gt;mature&lt;/b&gt;, postmitotic neurons." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="27238" end="27243" sStart="null" offset="399" sid="r9.level.n.0937" wn="1" wnkey="level%1:07:00::" text="A 2-fold to 3-fold increase of ?-catenin level in the mammary glands of transgenic mice also results in aberrant differentiation and tumors [ 34 35 ] . Thus while it is possible that a greater than 2-fold increase in ?-catenin level would have a neoplastic effect on adult neurons, evidence from other transgenic models suggests the increased protein level in our mice could be sufficient for tumor promotion." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="30433" end="30439" sStart="null" offset="63" sid="r9.level.n.0889" wn="1" wnkey="level%1:07:00::" text="It is possible, however, that higher ?-catenin protein levels, or expression in undifferentiated precursor cells in utero , would result in tumor formation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="12696" end="12702" sStart="null" offset="41" sid="r9.level.n.0497" wn="1" wnkey="level%1:07:00::" text="Transgenic protein was expressed at high levels in the brains of WT-1, Mut-1 and Mut-2 mice and at lower levels in the WT-2 and Mut-3 lines." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="26458" end="26463" sStart="null" offset="153" sid="r9.level.n.0148" wn="2" wnkey="level%1:26:01::" text="Harada and colleagues documented intestinal polyposis in ?-catenin transgenic mice with a less than 2-fold increase in ?-catenin protein level in the polyps [ 33 ] . The authors point out that because the transgene was only expressed in a fraction of cells in this tissue, protein levels are likely higher in some epithelial cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="13648" end="13653" sStart="null" offset="36" sid="r9.level.n.0510" wn="1" wnkey="level%1:07:00::" text="Some variation in ?-catenin protein level was seen between animals, but this was not related to age and high expression levels were seen at all time points evaluated (6 weeks to 12 months; data not shown)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="21456" end="21460" sStart="null" offset="34" sid="r10.high.j.0523" wn="1" wnkey="high%3:00:02::" text="In the transgenic line expressing high levels of human wild-type ?-catenin, significant amounts of FLAG epitope-tagged protein were detected, however overall ?-catenin levels were only slightly increased, suggesting the mechanisms that normally regulate ?-catenin level were able to compensate for the addition of the human transgenic protein." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="20745" end="20753" sStart="null" offset="149" sid="r11.function.n.0852" wn="2" wnkey="function%1:07:00::" text="These animals all died within 9 months from lymphomas or other extra-CNS neoplasms known to be associated with abrogation of p53 function." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="26853" end="26857" sStart="null" offset="14" sid="r9.fold.v.0983" wn="2147483645" wnkey="null" text="A 2-fold to 3-fold increase of ?-catenin level in the mammary glands of transgenic mice also results in aberrant differentiation and tumors [ 34 35 ] . Thus while it is possible that a greater than 2-fold increase in ?-catenin level would have a neoplastic effect on adult neurons, evidence from other transgenic models suggests the increased protein level in our mice could be sufficient for tumor promotion." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="26423" end="26427" sStart="null" offset="118" sid="r9.fold.v.0744" wn="2147483645" wnkey="null" text="Harada and colleagues documented intestinal polyposis in ?-catenin transgenic mice with a less than 2-fold increase in ?-catenin protein level in the polyps [ 33 ] . The authors point out that because the transgene was only expressed in a fraction of cells in this tissue, protein levels are likely higher in some epithelial cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="12067" end="12071" sStart="null" offset="186" sid="r9.fold.v.0646" wn="" wnkey="null" text="This reporter plasmid contains three optimal TCF binding sites [ 28 ] . TOPFLASH luciferase activity was activated 41-fold by S37F mutant ?-catenin and 3.8 fold by wild-type ?-catenin in DAOY cells (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="27063" end="27067" sStart="null" offset="224" sid="r9.fold.v.0526" wn="" wnkey="null" text="A 2-fold to 3-fold increase of ?-catenin level in the mammary glands of transgenic mice also results in aberrant differentiation and tumors [ 34 35 ] . Thus while it is possible that a greater than 2-fold increase in ?-catenin level would have a neoplastic effect on adult neurons, evidence from other transgenic models suggests the increased protein level in our mice could be sufficient for tumor promotion." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="26843" end="26847" sStart="null" offset="4" sid="r9.fold.v.0330" wn="" wnkey="null" text="A 2-fold to 3-fold increase of ?-catenin level in the mammary glands of transgenic mice also results in aberrant differentiation and tumors [ 34 35 ] . Thus while it is possible that a greater than 2-fold increase in ?-catenin level would have a neoplastic effect on adult neurons, evidence from other transgenic models suggests the increased protein level in our mice could be sufficient for tumor promotion." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="15494" end="15499" sStart="null" offset="117" sid="r10.find.v.0494" wn="2" wnkey="find%2:39:02::" text="In the cerebellum 20-40% of the granule cell nuclei were positive, and positive nuclei were also found scattered throughout the molecular layer (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="18510" end="18516" sStart="null" offset="28" sid="r10.common.j.0214" wn="4" wnkey="common%5:00:00:familiar:02" text="While the waltzing was most common in mice expressing mutant ?-catenin, one non-transgenic mouse also exhibited a loose circling behavior." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="24840" end="24847" sStart="null" offset="64" sid="r9.appear.v.0672" wn="1" wnkey="appear%2:39:00::" text="Thus in our transgenic animals, aberrant Wnt activation appears to be limited to mature, postmitotic neurons." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="2854" end="2861" sStart="null" offset="504" sid="null" wn="2" wnkey="absence%1:04:00::" text="APC mutations have been identified in medulloblastoma cell lines and up to 4% of sporadic medulloblastomas [ 16 17 ] . Furthermore, point mutations or small deletions in ?- catenin exon 3 have been identified in 5-10% of sporadic medulloblastomas and in supratentorial primitive neuroectodermal tumors (PNETs) [ 17 18 19 ] . Finally, large deletions in AXIN were recently found in 12% of sporadic medulloblastomas [ 20 ] . In the absence of Wnt signaling ?-catenin is sequestered in the cytoplasm, and nuclear translocation of ?-catenin has been used to monitor activation of the Wnt pathway in a number of different tumor types." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="2854" end="2861" sStart="null" offset="504" sid="null" wn="1" wnkey="absence%1:26:00::" text="APC mutations have been identified in medulloblastoma cell lines and up to 4% of sporadic medulloblastomas [ 16 17 ] . Furthermore, point mutations or small deletions in ?- catenin exon 3 have been identified in 5-10% of sporadic medulloblastomas and in supratentorial primitive neuroectodermal tumors (PNETs) [ 17 18 19 ] . Finally, large deletions in AXIN were recently found in 12% of sporadic medulloblastomas [ 20 ] . In the absence of Wnt signaling ?-catenin is sequestered in the cytoplasm, and nuclear translocation of ?-catenin has been used to monitor activation of the Wnt pathway in a number of different tumor types." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="7376" end="7383" sStart="null" offset="123" sid="r11.absence.n.0770" wn="1" wnkey="absence%1:26:00::" text="Human ?-catenin exon 3 was PCR-amplified from transgenic mouse DNA and sequenced to verify presence or absence of the codon 37 mutations." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="2854" end="2861" sStart="null" offset="504" sid="r11.absence.n.0380" wn="1" wnkey="absence%1:26:00::" text="APC mutations have been identified in medulloblastoma cell lines and up to 4% of sporadic medulloblastomas [ 16 17 ] . Furthermore, point mutations or small deletions in ?- catenin exon 3 have been identified in 5-10% of sporadic medulloblastomas and in supratentorial primitive neuroectodermal tumors (PNETs) [ 17 18 19 ] . Finally, large deletions in AXIN were recently found in 12% of sporadic medulloblastomas [ 20 ] . In the absence of Wnt signaling ?-catenin is sequestered in the cytoplasm, and nuclear translocation of ?-catenin has been used to monitor activation of the Wnt pathway in a number of different tumor types." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-33.anc" start="2854" end="2861" sStart="null" offset="504" sid="null" wn="1" wnkey="absence%1:26:00::" text="APC mutations have been identified in medulloblastoma cell lines and up to 4% of sporadic medulloblastomas [ 16 17 ] . Furthermore, point mutations or small deletions in ?- catenin exon 3 have been identified in 5-10% of sporadic medulloblastomas and in supratentorial primitive neuroectodermal tumors (PNETs) [ 17 18 19 ] . Finally, large deletions in AXIN were recently found in 12% of sporadic medulloblastomas [ 20 ] . In the absence of Wnt signaling ?-catenin is sequestered in the cytoplasm, and nuclear translocation of ?-catenin has been used to monitor activation of the Wnt pathway in a number of different tumor types." />
  </sentences>
</list>